Eyegate Pharmaceuticals, Inc. Warrants
EYEGW
EYEGW was delisted on the 5th of August, 2020.
3 hedge funds and large institutions have $7K invested in Eyegate Pharmaceuticals, Inc. Warrants in 2018 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
46% less capital invested
Capital invested by funds: $13K → $7K (-$6K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$277 |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIC
1
AWM Investment Company
New York
| $7K | – | – | – |
|
|
2
UBS Group
Zurich,
Switzerland
| – | +$277 | +4,300 | New |
|
EYEGW Hedge Fund Activity: Q3 2018 in Review
3 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) for Q3 2018, worth a combined $7K — down 46% from $13K a quarter earlier.
Fund positioning in EYEGW was balanced in Q3 2018: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $277.
- 3 institutional investors held Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) as of Q3 2018, unchanged from Q2 2018.
- Funds reported $7K of Eyegate Pharmaceuticals, Inc. Warrants stock for Q3 2018, down 46% quarter-over-quarter.
- 1 fund opened new Eyegate Pharmaceuticals, Inc. Warrants positions in Q3 2018 and 1 closed out, a net change of 0 holders.
- The largest Eyegate Pharmaceuticals, Inc. Warrants buyer in Q3 2018 was UBS Group, an estimated $277 added.
Based on aggregated 13F filings for Q3 2018.